Literature DB >> 17235550

Fifteen-year remission of a steroid-resistant nephrotic syndrome sustained by cyclosporine A.

Jens Drube1, Christoph Geerlings, Ruth Taylor, Michael Mengel, Jochen H H Ehrich.   

Abstract

Many children with a late steroid-resistant nephrotic syndrome (SRNS) and focal glomerulosclerosis have a poor prognosis and enter end-stage renal failure (ESRF) within five years. Reports are scarce on the long-term follow-up of patients entering remission while receiving immunosuppressive therapy after steroids have failed. A two-year-old boy with focal and segmental glomerulosclerosis having both late steroid and cyclophosphamide resistance entered complete remission of the SRNS almost two years after starting induction therapy with cyclosporine A (CSA). During the 15-year follow-up, the patient experienced five relapses during CSA maintenance therapy. All relapses were successfully treated within 10 days by intravenous methylprednisolone pulses in addition to CSA. The relapses were accompanied by a drop in the glomerular filtration rate (GFR). At the age of 18 years, the patient had grade II chronic kidney disease (GFR=61 ml/min/1.73 m2). At the age of 14 years, mycophenolate mofetil (MMF) was added to the maintenance therapy and the CSA dosage was reduced. Two renal biopsies at the ages of 10 and 18 years failed to detect CSA nephrotoxicity. We conclude that children with SRNS may have long-term benefit from a combination therapy using intravenous methylprednisolone pulses and CSA.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17235550     DOI: 10.1007/s00467-006-0398-6

Source DB:  PubMed          Journal:  Pediatr Nephrol        ISSN: 0931-041X            Impact factor:   3.714


  12 in total

1.  Treatment practices of FSGS among North American pediatric nephrologists.

Authors:  V M Vehaskari
Journal:  Pediatr Nephrol       Date:  1999-05       Impact factor: 3.714

2.  Urinary albumin excretion predicts cardiovascular and noncardiovascular mortality in general population.

Authors:  Hans L Hillege; Vaclav Fidler; Gilles F H Diercks; Wiek H van Gilst; Dick de Zeeuw; Dirk J van Veldhuisen; Rijk O B Gans; Wilbert M T Janssen; Diederick E Grobbee; Paul E de Jong
Journal:  Circulation       Date:  2002-10-01       Impact factor: 29.690

Review 3.  Focal segmental glomerulosclerosis: pathogenesis and treatment.

Authors:  Corinne Benchimol
Journal:  Curr Opin Pediatr       Date:  2003-04       Impact factor: 2.856

Review 4.  Nephrotic focal segmental glomerulosclerosis in 2004: an update.

Authors:  Alain Meyrier
Journal:  Nephrol Dial Transplant       Date:  2004-07-27       Impact factor: 5.992

5.  Differential risk of remission and ESRD in childhood FSGS.

Authors:  Debbie S Gipson; Hyunsook Chin; Trevor P Presler; Caroline Jennette; Maria E Ferris; Susan Massengill; Keisha Gibson; David B Thomas
Journal:  Pediatr Nephrol       Date:  2006-01-05       Impact factor: 3.714

6.  Predictive factors of chronic kidney disease in primary focal segmental glomerulosclerosis.

Authors:  Marcelo M Abrantes; Luis Sergio B Cardoso; Eleonora M Lima; José M Penido Silva; José S Diniz; Eduardo A Bambirra; Eduardo A Oliveira
Journal:  Pediatr Nephrol       Date:  2006-05-30       Impact factor: 3.714

Review 7.  Mycophenolate mofetil therapy in frequently relapsing steroid-dependent and steroid-resistant nephrotic syndrome of childhood: current status and future directions.

Authors:  Asha Moudgil; Arvind Bagga; Stanley C Jordan
Journal:  Pediatr Nephrol       Date:  2005-06-24       Impact factor: 3.714

8.  Cyclosporine in patients with steroid-resistant nephrotic syndrome: an open-label, nonrandomized, retrospective study.

Authors:  Gian Marco Ghiggeri; Paolo Catarsi; Francesco Scolari; Gianluca Caridi; Roberta Bertelli; Alba Carrea; Simone Sanna-Cherchi; Francesco Emma; Landino Allegri; Giovanni Cancarini; Gian Franco Rizzoni; Francesco Perfumo
Journal:  Clin Ther       Date:  2004-09       Impact factor: 3.393

9.  High incidence of initial and late steroid resistance in childhood nephrotic syndrome.

Authors:  Jung Sue Kim; Christine A Bellew; Douglas M Silverstein; Diego H Aviles; Frank G Boineau; V Matti Vehaskari
Journal:  Kidney Int       Date:  2005-09       Impact factor: 10.612

Review 10.  Interventions for steroid-resistant nephrotic syndrome: a systematic review.

Authors:  Doaa Habashy; Elisabeth M Hodson; Jonathan C Craig
Journal:  Pediatr Nephrol       Date:  2003-06-26       Impact factor: 3.714

View more
  4 in total

1.  Rituximab for refractory cases of childhood nephrotic syndrome.

Authors:  Jameela A Kari; Salah M El-Morshedy; Sherif El-Desoky; Hammad O Alshaya; Khawla A Rahim; Burhan M Edrees
Journal:  Pediatr Nephrol       Date:  2011-01-31       Impact factor: 3.714

Review 2.  Corticosteroid-resistant nephrotic syndrome with focal and segmental glomerulosclerosis : an update of treatment options for children.

Authors:  Jochen H H Ehrich; Lars Pape; Mario Schiffer
Journal:  Paediatr Drugs       Date:  2008       Impact factor: 3.022

3.  Clinical practice guideline for pediatric idiopathic nephrotic syndrome 2013: medical therapy.

Authors:  Kenji Ishikura; Shinsuke Matsumoto; Mayumi Sako; Kazushi Tsuruga; Koichi Nakanishi; Koichi Kamei; Hiroshi Saito; Shuichiro Fujinaga; Yuko Hamasaki; Hiroko Chikamoto; Yasufumi Ohtsuka; Yasuhiro Komatsu; Toshiyuki Ohta; Takuhito Nagai; Hiroshi Kaito; Shuji Kondo; Yohei Ikezumi; Seiji Tanaka; Yoshitsugu Kaku; Kazumoto Iijima
Journal:  Clin Exp Nephrol       Date:  2015-02       Impact factor: 2.617

4.  Cyclophosphamide versus cyclosporine A therapy in steroid-resistant nephrotic syndrome: a retrospective study with a mean 5-year follow-up.

Authors:  Yanwei Liu; Ruikun Yang; Chen Yang; Shuhong Dong; Ying Zhu; Mingdong Zhao; Fenglai Yuan; Keke Gui
Journal:  J Int Med Res       Date:  2018-09-05       Impact factor: 1.671

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.